N-4-[(2H-1,3-benzodioxol-5-yl)sulfamoyl]phenylacetamide
≥97%
- Product Code: 216020
CAS:
333747-86-7
| Molecular Weight: | 334.35 g./mol | Molecular Formula: | C₁₅H₁₄N₂O₅S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00245824 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature |
Product Description:
Used as an intermediate in the synthesis of sulfa-based pharmaceuticals, particularly in the development of carbonic anhydrase inhibitors. These inhibitors are applied in the treatment of glaucoma, epilepsy, and certain types of edema. The compound’s structure allows for effective binding to enzyme active sites, enhancing its pharmacological activity. Also explored for its potential in anticancer research due to its ability to modulate tumor-associated carbonic anhydrase isoforms.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | ฿7,380.00 |
+
-
|
N-4-[(2H-1,3-benzodioxol-5-yl)sulfamoyl]phenylacetamide
Used as an intermediate in the synthesis of sulfa-based pharmaceuticals, particularly in the development of carbonic anhydrase inhibitors. These inhibitors are applied in the treatment of glaucoma, epilepsy, and certain types of edema. The compound’s structure allows for effective binding to enzyme active sites, enhancing its pharmacological activity. Also explored for its potential in anticancer research due to its ability to modulate tumor-associated carbonic anhydrase isoforms.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :